Comments on Strang et al. (2016): 'Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?'

Maya Doe-Simkins; Caleb Banta-Green; Corey S Davis; Traci C Green; Alexander Y Walley

doi:10.1111/add.13399

Comments on Strang et al. (2016): 'Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?'

Addiction. 2016 Oct;111(10):1879-80. doi: 10.1111/add.13399. Epub 2016 Jul 14.

Authors

Maya Doe-Simkins¹, Caleb Banta-Green², Corey S Davis³, Traci C Green⁴, Alexander Y Walley⁵

Affiliations

¹ Heartland Health Outreach, Chicago, IL, USA. mdoesimkins@gmail.com.
² University of Washington, Alcohol and Drug Abuse Institute, Seattle, WA, USA.
³ Network for Public Health Law, Southeastern Region, Chapel Hill, NC, USA.
⁴ Boston Medical Center, CARE Unit, General Internal Medicine, Boston, MA, USA.
⁵ Boston University School of Medicine, Department of Emergency Medicine, Boston, MA, USA.

PMID: 27412451
DOI: 10.1111/add.13399

No abstract available

Keywords: Ethics and research; heroin overdose; layperson naloxone; nasal naloxone; off-label use of medicine; opioid overdose; overdose prevention; people who use drugs.

Publication types

Letter
Research Support, U.S. Gov't, P.H.S.
Comment

MeSH terms

Analgesics, Opioid
Drug Overdose
Heroin
Humans
Naloxone*
Narcotic Antagonists*

Substances

Analgesics, Opioid
Narcotic Antagonists
Naloxone
Heroin

Grants and funding

R18 HS024021/HS/AHRQ HHS/United States